Publicacións en colaboración con investigadores/as de Hospital Universitario San Juan de Alicante (7)

2023

  1. Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase

    Primary Care Diabetes, Vol. 17, Núm. 4, pp. 366-372

  2. Effect of dapagliflozin on COVID-19 infection and risk of hospitalization

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 9, pp. 2335-2342

2022

  1. Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry

    European Journal of Clinical Investigation, Vol. 52, Núm. 12

  2. Impact of the COVID-19 pandemic in the lipid control of the patients that start PCSK9 inhibitors

    Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 5, pp. 245-252

  3. Sex Differences in Low-Density Lipoprotein Cholesterol Reduction with PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry

    Journal of Cardiovascular Pharmacology, Vol. 79, Núm. 4, pp. 523-529

2020

  1. Estimation of the major cardiovascular events prevention with Inclisiran

    Atherosclerosis, Vol. 313, pp. 76-80

  2. Prevention of myocardial infarction and stroke with PCSK9 inhibitors treatment: a metanalysis of recent randomized clinical trials

    Journal of Diabetes and Metabolic Disorders, Vol. 19, Núm. 2, pp. 759-765